ArticleDiscover oncology2026
Immune-related LncRNA signatures define tumor microenvironment subtypes and predict immunotherapy response in NSCLC.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tumor-immune crosstalk in lung cancer: emerging roles of long non-coding RNAs.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLong non-coding RNAs (lncRNAs) play critical roles in immune regulation and tumor microenvironment (TME) remodeling. However, their contribution to non-small cell lung cancer (NSCLC) heterogeneity and immunotherapy response remains unclear.
methodsWe integrated transcriptomic data from TCGA and GEO cohorts after batch correction. Immune-related lncRNAs were identified and used for unsupervised clustering to define molecular subtypes. Survival outcomes, immune infiltration, somatic mutation profiles, and predicted drug sensitivities were compared among subtypes. Weighted gene co-expression network analysis (WGCNA) and pathway enrichment were performed to identify hub genes and biological processes.
resultsThree lncRNA-defined subtypes were identified with distinct TME characteristics: an immune-inflamed subtype enriched in B/T cells and HLA expression, an immune-escape subtype with interferon-driven MHC upregulation, and an immune-desert subtype with minimal immune infiltration. These subtypes were significantly associated with prognosis, genomic alterations, and clinical features. Cluster A (predominantly LUAD) exhibited superior overall survival and higher predicted immunotherapy sensitivity, while Cluster C (enriched in LUSC) showed higher predicted sensitivity to chemotherapy. Hub genes including SOX2, KRAS, KEAP1, and STAT1 were implicated in TME regulation. Drug sensitivity prediction suggested potential therapeutic stratification across clusters.
conclusionsImmune-related lncRNA signatures define novel NSCLC subtypes with distinct immune phenotypes and therapeutic responses. These findings suggest that lncRNA-based TME classification may complement PD-L1 and tumor mutational burden as predictive biomarkers for immunotherapy. Validation in prospective clinical cohorts is warranted to establish their translational utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.